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1. ABSTRACT 
Dementia with Lewy bodies (DLB) patients often experience visual hallucinations, 
which are related to decreased quality of life for patients and increased caregiver 
distress. The pathological changes that contribute to visual hallucinations are not 
known, but several hypotheses implicate deficient attentional processing. The superior 
colliculus has a role in visual attention, planning eye movements and has been directly 
implicated in several models of visual hallucinations. Therefore, the present study 
sought to identify neurodegenerative changes that may contribute to hallucinations in 
DLB. Post-mortem superior colliculus tissue from 13 control, 10 DLB and 10 
Alzheimer’s disease (AD) cases was evaluated using quantitative neuropathological 
methods. α-synuclein and tau deposition was more severe in deeper layers of the 
superior colliculus. DLB cases had neuronal density reductions in the stratum griseum 
intermedium, an important structure in directing attention towards visual targets. In 
contrast, neuronal density was reduced in all laminae of the superior colliculus in AD. 
These findings suggest that regions involved in directing attention towards visual 
targets are subject to neurodegenerative changes in DLB. Considering several 
hypotheses of visual hallucinations implicate dysfunctional attention towards external 
stimuli, these findings may provide evidence of pathological changes that contribute 
to the manifestation of visual hallucinations in DLB.   
2. INTRODUCTION 
Dementia with Lewy bodies (DLB) is the second most common progressive 
neurodegenerative dementia after Alzheimer’s disease (AD), accounting for 
approximately 4.2% of all dementia cases (1, 2). DLB is clinically characterized by 
three core symptoms of fluctuating cognition, parkinsonism and complex visual 
hallucinations (3). The defining histological feature of DLB, along with Parkinson’s 
disease (PD) and Parkinson’s disease dementia (PDD), is the presence of 
intracytoplasmic α-synuclein-containing inclusions termed Lewy bodies (4). The 
topographical distribution of Lewy body-related pathology in the respective disorders 
is thought to underlie the patterns of clinical manifestations (5). Lewy body pathology 
affects brainstem, limbic and neocortical regions in DLB (6), often in combination with 
the two hallmark histological features of AD, amyloid-β and tau pathology (3). 
Visual attention is more abnormal in DLB than in AD or PD (7), and DLB patients show 
greater impairment in filtering distracting visual stimuli compared to AD or control 
patients (8). Deficits in visual attention have been suggested to contribute to the 
manifestation of complex visual hallucinations in DLB (9, 10). Complex visual 
hallucinations are common in DLB (11), occurring in 60-80% of cases (12), and 
typically consist of objects, such as animals, people and faces (13). Visual 
hallucinations are related to impaired quality of life for DLB patients (14, 15) and 
contribute to caregiver distress (16), and thus represent an important therapeutic 
target, yet their pathological etiology is poorly understood.   
The superior colliculus has a distinctive laminar structure consisting of seven layers in 
three major grey matter strata: the stratum griseum superficiale (SGS), the stratum 
griseum intermedium (SGI) and the stratum griseum profundum (SGP), interspersed 
with predominantly fibre-rich layers (17). The superior colliculus may be subject to 
neurodegenerative changes in DLB as increased saccadic latency, which has been 
reported in DLB (18), has also been observed in non-human primates following 
chemical inactivation of the superior colliculus  (19). The superior colliculus is also 
involved in attentional functions that are impaired in DLB, such as target selection and 
the filtering of distracting stimuli (17). One model has directly implicated dysfunction 
of the dorsal attentional network, with which the superior colliculus is thought to 
interact, in the manifestation of visual hallucinations in DLB (20). The pathway from 
the retina to the inferior pulvinar, routed through the SGS, has also been directly 
implicated in the manifestation of hallucinations in Lewy body disease (21).  
The aim of the present study was to identify whether the superior colliculus is subject 
to neurodegenerative changes in DLB using stereological measures of cell density 
and densitometric analysis of neuropathological lesions. Cell density and 
neuropathological data were then compared to neuropsychological data obtained 
during life, and the known function of the individual laminae of the superior colliculus, 
to determine the relationship between neurodegenerative changes and clinical 
features. DLB cases were compared to aged comparison cases and ‘disease 
comparison’ AD cases to elucidate whether degenerative changes occur to the 
superior colliculus in DLB and their relationship to its distinct clinical manifestation.    
  
3. METHODS 
Tissue preparation 
Human post-mortem tissue was obtained from a convenience sample from the 
Newcastle Brain Tissue Resource (NBTR) and ethical approval was granted by 
Newcastle University ethics board and the Joint Ethics Committee of Newcastle and 
North Tyneside Health Authority (ref: 08/H0906/136). DLB and AD subjects had been 
part of several prospective clinical studies, and had received detailed clinical 
assessments according to international consensus guidelines (3, 22) and case note 
review after death. Cases with psychiatric or neurodegenerative comorbidities were 
excluded from the present study. Neuropathological assessment was performed 
according to standardized neuropathological diagnostic procedures (3, 23-26). Clinical 
and pathological data was collated to establish a clinico-pathological consensus 
diagnosis. Three groups of cases were included in the present study: 10 DLB cases, 
10 AD cases and 13 clinically confirmed aged comparison cases that showed none, 
or only low, age-associated neurodegenerative pathology at post-mortem examination. 
Case details are contained in Table 1.  
At autopsy, the upper midbrain was dissected from the cerebrum at the level of the 
fourth cranial nerve, along a line from the junction of the mammillary body running 
posteriorly to the upper part of the superior colliculus (Fig. 1). For stereological 
analysis, 3x 30 μm adjacent sections were cut and stained with cresyl violet. 6 μm 
sections were stained with antibodies (KM51 anti-α-synuclein, Leica, UK 1:250; AT8 
anti-phosphorylated tau, Autogen, MA, USA, 1:4000; 4G8 anti-amyloid-β, Covance, 
NJ, USA, 1:15000) using Menarini Menapath polymer detection kits (Menarini, 
Berkshire, UK). 
 
Stereology 
Stereological estimates of neuronal density were made in each of the three prominent 
grey matter laminae of the superior colliculus: the SGS, the SGI and SGP, based on 
their cytoarchitecture and laminar organization (27). In cresyl violet sections, neurons 
were differentiated from glia by the presence of Nissl substance within cytoplasm, a 
pale nucleus, and a single identifiable nucleolus (28).  
Stereological analysis was conducted using a Zeiss AxioVision Z.1 microscope 
equipped with a motorized stage (Zeiss, Oberkochen, Germany), coupled to a 
computer with Stereologer software (Bethesda, MA, USA). The rater (D.E.), working 
together with the senior investigator trained in stereological methodology (A.A.K.), 
traced an outline around the region of interest (i.e. SGS, SGI or SGP) using a 2.5x 
objective. Disector frames were placed in a uniform, random arrangement to calculate 
the density of cells within a defined region (as described previously (28)). Neuronal 
counts were conducted at 63x oil-immersion objective using the optical disector probe. 
Glial cell counts were calculated in all laminae in disector frames of 3500 μm2, with 
neuron counts calculated in disector frames of 1900 μm2. Section thickness did not 
vary across disease groups any layer. The mean coefficients of error (CE) for neuronal 
and glial cell estimates was calculated using the Gundersen-Jensen method (29). The 
mean coefficient of error values for all stereologically-obtained data showed 
acceptable levels of accuracy (<0.15) (30). 
To evaluate whether neuronal density changes occur as a result of increasing age, 
post-mortem delay or length of time fixed in formalin, correlational analyses were 
conducted between these variables and neuronal density in each layer of the superior 
colliculus across all cases. To assess whether neuronal density is altered based on 
the duration of disease, correlation analyses were conducted between neuronal 
density in each layer and duration of disease in DLB and AD cases. 
  
Neuropathology 
To quantify neuropathological lesions, images of each stratum of the superior 
colliculus were taken on a Zeiss AxioVision Z.1 microscope using a DsFi1 camera 
(Nikon, Tokyo, Japan). Stereologer software was used to delineate a region of interest 
with a 2.5x objective, prior to placement of disector frames in a uniform, random 
arrangement. This method prevented the introduction of bias by giving every area of 
the region of interest an equal probability of being sampled for analysis. In all cases, 
amyloid-β, tau and α-synuclein were measured using a 20x objective. Approximately 
eight images were taken per lamina per case within the disector frames and analyzed 
using ImagePro Plus v.4.1 image analysis system (Media Cybernetics, Bethesda, MA, 
USA). Using previously published techniques (31) the mean percentage area of 
immunopositivity was determined by standardizing red-green-blue (RGB) thresholds 
per antibody and applying to all sections per case. Each case thus had a mean value 
generated per antibody for each stratum. 
The percentage area immunoreactive for α-synuclein, tau and amyloid-β was 
compared across disease groups to evaluate the vulnerability of the superior colliculus 
to neurodegenerative pathology in DLB, AD and comparison cases. Correlational 
analyses were conducted between neuropathological and stereological data to 
evaluate the relationship between neuropathology and neuronal density in each 
disease group. 
 
Clinico-pathological correlation 
DLB patients had been recruited for clinical research studies, during which some had 
received serial assessments of visual hallucination severity and frequency at frequent 
intervals until death (13, 32). Due to the hypothesized role of the superior colliculus in 
the manifestation of visual hallucinations in Lewy body disease (21), neuronal density 
and pathological burden were correlated with final neuropsychiatric inventory 
hallucinations subscale score (NPI [hall]) in all layers of the superior colliculus (33) in 
DLB cases, where available. Final NPI (hall) scores were available for 8/10 DLB cases. 
The mean interval from final NPI assessment to death was 7.81±3.45 months. The 
relationship between visual hallucinations and the superior colliculus was not explored 
in AD as visual hallucinations are not a core feature of AD, and were less frequently 
assessed. Additionally, as a separate disease entity, it is possible that visual 
hallucinations in AD, when present, have a different underlying pathogenesis to that 
in DLB. 
 
Statistics  
Inspection of Q-Q plots and Shapiro-Wilk tests suggested that demographic, 
stereological and neuropathological data were either not normally distributed or did 
not have homogeneity of variance. Therefore, Kruskal-Wallis (KW) tests with post-hoc 
Mann-Whitney U tests were employed for these data. Due to the relatively small 
sample size, corrections for multiple comparisons were not applied. However, effect 
sizes were reported using Cohen’s d. For comparisons between different laminae, 
Friedman tests with post-hoc Wilcoxon signed-ranks tests were performed.  
  
4. RESULTS 
Demographics 
No significant differences were found between groups in age at death (KW χ²=2.461, 
df=2, p=0.292), post-mortem delay (KW χ²=2.708, df=2, p=0.258) or length of time 
fixed in formalin (KW χ²=0.472, df=2, p=0.790; Table 1).  
 
Stereology  
In the SGS, there was a significant main effect of diagnosis on neuronal density (KW 
χ²=6.579, df=2, p=0.037). No significant difference was found between comparison 
cases and DLB. AD cases (mean[x100]=0.0054 [95% CI 0.0047-0.0061]) had reduced 
neuronal density compared to comparison cases (mean[x100]=0.0067 [95% CI 
0.0059-0.0076]; U=27.000, p=0.018, d=1.014). There was no significant difference in 
neuronal density between DLB and AD in the SGS. There was no significant main 
effect of diagnosis on glial density in the SGS (Fig. 2). 
In the SGI, there was a significant main effect of diagnosis on neuronal density (KW 
χ²=13.046, df=2, p=0.001). DLB (mean[x100]=0.0030 [95% CI 0.0025-0.0034]; 
U=18.500, p=0.003, d=1.08), and AD (mean[x100]=0.0029 [95% CI 0.0026-0.0032]; 
U=13.5, p=0.001, d=1.24) had reduced neuronal density compared to comparison 
cases (mean[x100]=0.0036 [95% CI 0.0033-0.0038]). There was no significant 
difference in neuronal density between DLB and AD in the SGI. There was no 
significant main effect of diagnosis on glial density in the SGI (Fig. 2). 
In the SGP, there was a significant main effect of diagnosis on neuronal density (KW 
χ²=6.600, df=2, p=0.037). No significant difference was found between comparison 
cases and DLB. AD cases (mean[x100]=0.0028 [95% CI 0.0025-0.0031]) had reduced 
neuronal density compared to comparison cases (mean[x100]=0.0036 [95% CI 
0.0031-0.0040]; U=27.000, p=0.018, d=1.12). There was no significant difference in 
neuronal density between DLB and AD in the SGP. There was no significant main 
effect of diagnosis on glial density in the SGP (Fig. 2). 
In DLB cases, duration of disease was significantly negatively correlated with neuronal 
density in the SGI (rs=-0.726, N=10, p=0.018). However, no significant correlations 
were found between duration of disease and neuronal density in the SGS and SGP. 
In AD, duration of disease was not significantly correlated with neuronal density in any 
layer.  
 
Neuropathology  
Comparisons of neuropathology between groups are detailed in Table 2.  
In DLB cases, there was a significant difference in the degree of α-synuclein pathology 
across the three layers (Friedman χ²=12.600, df=2, p=0.002; Fig. 3A-C). The SGI 
(mean=0.0268 [95% CI 0.0180-0.0356]; Wilcoxon Z=2.803, p=0.005, d=0.85), and the 
SGP (mean=0.0317 [95% CI 0.0108-0.0525]; Wilcoxon Z=2.497, p=0.013, d=1.09), 
had a significantly greater burden of α-synuclein pathology than the SGS 
(mean=0.0090 [95% CI 0.0025-0.0155]). There was no significant difference in the 
burden of α-synuclein pathology between the SGI and SGP. There were no significant 
correlations between α-synuclein pathology and neuronal density in any experimental 
group.   
Across DLB, AD and comparison cases, there was a significant difference in the 
degree of tau pathology between the three layers (Friedman χ²=26.375, p<0.001; Fig. 
3D-F). The SGI (mean=0.0929 [95% CI 0.0074-0.1783]; Wilcoxon Z=4.330, p<0.001, 
d=0.32) and SGP (mean=0.1241 [95% CI 0.0130-0.2352]; Wilcoxon Z=4.031, p<0.001, 
d=0.46) had a significantly greater burden of tau pathology than the SGS 
(mean=0.0207 [95% CI 0.0038-0.0376]). There was no significant difference in the 
burden of tau pathology between the SGI and SGP. Tau pathology was significantly 
negatively correlated with neuronal density in the SGI in all cases (rs=-0.404, N=33, 
p=0.022) and SGP (rs=-0.451, N=33, p=0.009). However, there was no significant 
relationship between tau pathology and neuronal density in the SGS.      
Across DLB, AD and comparison cases, there was no significant difference in amyloid-
β expression across the three layers of the superior colliculus (Fig. 3G-I). There were 
no significant correlations between amyloid-β pathology and neuronal density in any 
experimental group.  
 
Clinico-pathological relationships 
There were no significant correlations between age at death, post-mortem delay and 
fixation time in formalin, and neuronal density in any layer of the superior colliculus. 
In DLB cases, NPI (hall) score was significantly positively correlated with neuronal 
density in the SGS (rs=0.874, N=8, p=0.005). No other stereological or pathological 
variables were correlated with NPI (hall) score in DLB cases. 
5. DISCUSSION 
This study demonstrates reductions in neuronal density in the SGI in DLB, compared 
to neuronal loss in all laminae in AD. α-synuclein pathology was not related to neuronal 
density in any layer in DLB, but tau was inversely related to neuronal density in the 
SGI and SGP. There was no relationship between α-synuclein pathology and 
hallucination severity and frequency, as assessed by NPI (hall). However, neuronal 
density in the SGS was positively correlated with the severity and frequency of visual 
hallucinations in DLB. Distinct topographical patterns of deposition were observed for 
α-synuclein and tau pathology, with the SGI and SGP affected more severely than the 
SGS.  
The SGS receives retinal input (34) and projects to the medial temporal visual area 
(area V5/MT) through the inferior pulvinar (35, 36) in a pathway thought to be involved 
in the non-conscious perception of motion (37). In contrast, the SGI and SGP receive 
inputs from wide-ranging cortical and sub-cortical regions, such as motor and 
association sensory cortices, the locus ceruleus and dorsal raphe (38), and have an 
important role in the selection of visual targets (39) and in directing the resulting motor 
output (40).  
Within the superior colliculus, neuropathological lesions occurred in a stereotypical 
manner, with higher levels of α-synuclein and tau found in the SGI and SGP compared 
to the SGS. This may reflect the SGI and SGP receiving inputs from the dorsal raphe, 
locus ceruleus and pedunculopontine nucleus, which are vulnerable to the 
accumulation of Lewy body and tau pathology (41, 42). In contrast, the SGS receives 
predominant innervation from the retina and primary visual cortex (17), which do not 
appear to accumulate significant Lewy body pathology in DLB, and develop tau 
pathology only at the final stage of AD pathology (43-46). As tau and α-synuclein may 
spread throughout the brain in a manner reminiscent of prion protein, these distinct 
patterns of deposition may reflect greater connectivity with areas that are vulnerable 
to early neuropathological lesion formation (47). However, a neuropathological study 
of the superior colliculus has reported greater tau pathology in the SGI and SGP in 
individuals with chronic traumatic encephalopathy, indicating that these laminae may 
have an intrinsic vulnerability to tau pathology (48). 
The present study has demonstrated that neuronal loss in the superior colliculus only 
occurs in the SGI in the DLB acses included in this study. This was in contrast to AD, 
where neuronal density reductions were found in all laminae of the superior colliculus. 
DLB had significantly increased tau in the SGI, but not in other layers of the superior 
colliculus. As tau was negatively correlated with neuronal density in the SGI and SGP 
across all cases, this may indicate that tau is driving neuronal density reductions in 
DLB. The greater levels of tau pathology in AD cases may similarly cause the 
reductions in neuronal density seen in all laminae of the superior colliculus.  
Previous studies in the LGN and primary visual cortex (31, 44) have not demonstrated 
neuronal loss in DLB. In contrast, neuronal loss has been identified in the lateral 
pulvinar (49) and in the SGI of the superior colliculus in DLB. One model of visual 
hallucinations has suggested that DLB patients have difficulty engaging the dorsal 
attentional network to focus attention on ambiguous stimuli, instead relying on the self-
referential default mode network (20). As the lateral pulvinar (50) and SGI (17) are 
implicated in visual attention and target selection, respectively, it is tempting to 
speculate that neuronal losses in these regions could impair directed attention toward 
visual targets. However, visual attentional measures were not conducted on the 
present cases, so it is not possible to confirm whether these patients were impaired in 
these faculties, or whether this related to more severe visual hallucinations. 
Additionally, visual hallucinations in DLB are unlikely to result purely from neuronal 
loss in the SGI and these changes likely act in concert with degenerative changes 
elsewhere in the visual system to elicit visual hallucinations.  
Visual dysfunction, including hallucinations, in Lewy body disease have been linked to 
dysfunctional pathways involved in blindsight, the phenomenon whereby a blind 
individual may react to moving or emotional visual stimuli (21). These pathways 
implicate the SGS, a region that has been found in the present study to be preserved 
in individuals with more severe and frequent visual hallucinations. This may indicate 
that dysfunction of this region, or the pathway through it, is crucial for the occurrence 
of visual hallucinations. The present study was conducted on a relatively small sample, 
so it is difficult to draw strong conclusions about the relationship between neuronal 
number in the SGS and visual hallucinations.   
This study was limited by the fact that the superior colliculus was sampled on three 
adjacent slides, rather than serially through the entire z-axis. As a result, volume and 
total neuronal number could not be estimated. This was due to the superior colliculus 
being routinely dissected on two different planes (coronal and axial) and the inherent 
value of upper midbrain tissue. Few cases were available that had NPI data on visual 
hallucinations obtained during life and this impacted the number of cases included in 
the study. However, the use of a comparator group that do not typically manifest visual 
hallucinations suggests that the reported findings may be specific to DLB.    
In summary, the present study has demonstrated that the superior colliculus is subject 
to neurodegenerative changes in DLB. Specifically, neuronal loss was only found in 
the SGI in DLB. In contrast, AD cases had neuronal loss in all layers. As the SGI is 
important in directing attention and aiding visual target selection, the present results 
may indicate dysfunction in these functions in DLB. As dysfunctional visual attention 
and target selection have been related to visual hallucinations in DLB, the present 
results may provide evidence of neuropathological changes that contribute to the 
manifestation of visual hallucinations in DLB. However, these changes are unlikely to 
induce visual hallucinations on their own, thus continued study of the visual system is 
necessary to further understand the pathological changes that cause visual 
hallucinations in DLB.    
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Figure legends 
Fig. 1: Upper midbrain section stained with Loyez’s hemotoxylin. The superior 
colliculus is circled. 
Fig. 2: Stereological analysis of neuronal density. Neuronal and glial cell density 
across experimental groups in each lamina. *p<0.05. 
Fig. 3: Images of pathology in a DLB case.  α-synuclein pathology is  less severe in 
the SGS (A) than the SGI (B) and SGP (C). Tau pathology is minimal throughout but 
is less severe in the SGS (D) than in the SGI (E) and SGP (F). Amyloid-β is 
observed in the SGS (G), SGI (H) and SGP (I) and shows less regional specificity 
than α-synuclein and tau. Scale bar = 50 
 
